- Details
- Alicia Morgans speaks with Umang Swami about a publication in Clinical Genitourinary Cancer examining the real-world effectiveness of enfortumab vedotin (EV) in advanced urothelial carcinoma. Using the Flatiron Health database, which includes data from 280 US cancer clinics, the study analyzes outcomes for 371 patients receiving EV as second-line therapy or beyond. The research demonstrates that E...
|
- Details
- Thomas Powles discusses an exploratory nectin-4 biomarker analysis from the EV-302 trial. The conversation examines the role of nectin-4 expression in enfortumab vedotin plus pembrolizumab (EV-Pembro) therapy for bladder cancer, highlighting consistent benefits across expression levels compared to chemotherapy. While over 90% of patients express high levels of nectin-4, the discussion emphasizes t...
|
- Details
- Ashish Kamat talks with Andrea Apolo about implementing new treatment standards in bladder cancer, focusing on the recent EV-302 and CheckMate-901 trials. Dr. Apolo explains how enfortumab vedotin plus pembrolizumab has emerged as the new standard of care for metastatic urothelial carcinoma, showing superior survival outcomes compared to traditional platinum-based chemotherapy. They explore the ch...
|
- Details
- Thomas Powles discusses the EV-302 trial data, (Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer) focusing on biomarker analyses for enfortumab vedotin (EV) plus pembrolizumab in urothelial cancer. Dr. Powles discusses the lack of discriminatory effect for PD-L1 and nectin-4 expression as biomarkers, noting that nectin-4 is nearly universally expressed in urothelial can...
|
- Details
- Daniel Petrylak discusses advancements in advanced urothelial cancer treatment by highlighting the success of enfortumab vedotin (EV), an antibody-drug conjugate targeting nectin-4, combined with pembrolizumab. This combination significantly improves response rates and survival compared to standard chemotherapy, with a 30% complete response rate and doubled median survival. Dr. Petrylak presents r...
|
- Details
- Ashish Kamat interviews Shilpa Gupta about the best of ASCO 2024 in advanced bladder cancer. Dr. Gupta discusses three abstracts: the CheckMate-901 trial's analysis of complete responders to Nivolumab plus gemcitabine-cisplatin in lymph node-only metastatic urothelial cancer; patient-reported outcomes from the EV-302 trial comparing enfortumab vedotin plus pembrolizumab to platinum chemotherapy; a...
|
- Details
- Zach Klaassen discusses the findings of the EV-302/KEYNOTE-A39 trial with Michiel Simon Van der Heijden. The trial addresses a critical gap in treatment for cisplatin-ineligible patients with advanced urothelial cancer. Historically, these patients, who often receive carboplatin-based chemotherapy, have faced poorer outcomes compared to those eligible for cisplatin. The EV-302 trial, however, trea...
|
- Details
- Pat Hensley discusses first-line systemic therapy selection for advanced urothelial carcinoma with Karima Oualla and Shilpa Gupta. They highlight cisplatin-based chemotherapy as the traditional mainstay but shift focus to the EV-302 trial, which explores enfortumab vedotin (EV) and pembrolizumab (pembro) as a new first-line combination. Dr. Oualla explains the mechanisms and significant efficacy o...
|
- Details
- Alicia Morgans introduces Jonathan Rosenberg who discusses the EV-302 trial. This Phase III trial, which Dr. Rosenberg explains, involved a comparison between enfortumab vedotin (EV) combined with pembrolizumab and traditional chemotherapy for untreated metastatic urothelial cancer patients. The results were striking, with a notable improvement in both progression-free and overall survival for pat...
|
- Details
- Cora Sternberg discusses the significant advancement in the treatment of urothelial carcinoma, focusing on enfortumab vedotin (EV) in combination with pembrolizumab. This combination, recently approved in the US as a first-line therapy, has shifted the treatment paradigm, offering a potent alternative to traditional platinum-based therapies. Dr. Sternberg highlights the importance of this developm...
|
